The Evolving Landscape in the Management & Treatment of Multiple Sclerosis - Payer Considerations for Providing Support to People with MS and Their Care Partners

Release Date: April 1, 2023
Expiration Date: September 30, 2024
Estimated Time to Complete Activity: 1.0 hour
Compatible with all modern browsers and mobile devices

Expert Faculty Presenters:


	Dana McCormick, RPh, FAMCP Director of Pharmacy Blue Cross Blue Shield of Texas Click here for biography

	Jacqueline A. Nicholas, MD, MPH System Chief Neuroimmunology & Multiple Sclerosis OhioHealth Multiple Sclerosis Center Click here for biography

	Melissa Barnhill, MPH Director of Mission Delivery and Community Engagement Multiple Sclerosis Association of America (MSAA) Click here for biography

Target Audience
This activity is designed to meet the educational needs of medical directors, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.

Statement of Need/Program Overview
Despite the availability of more than a dozen disease modifying therapies (DMTs), health care resource utilizations associated with MS is significant and continues to rise. In this activity, we will look at ways to develop and implement access and reimbursement policies that lower barriers to timely and patient-appropriate care.

Educational Objectives
After completing this activity, the participant should be better able to:

Assess how current and emerging therapies impact disease control and how they fit into the MS treatment algorithm.
Employ strategies to enhance multidisciplinary MS care management.
Evaluate improvements to continuity of care through minimizing treatment disruptions caused by changes in formulary status of a drug.
Illustrate how to reduce barriers between providers and payers by integrating data generated by specialty pharmacy partners into MS treatment decision making.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER), the Multiple Sclerosis Association of America (MSAA), and Impact Education, LLC. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional Continuing Education (IPCE)
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Physician Continuing Medical Education
Medical Education Resources designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit
Medical Education Resources designates this enduring activity for a maximum of 1.0 ANCC nursing contact hour. Nurses will be awarded contact hours upon successful completion of the activity

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 1.0 contact hour.

Pharmacy Credit

Medical Education Resources (MER) designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.

Universal Program Number: JA0003680-9999-23-151-H01-P
This activity is certified as Knowledge-based CPE.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings

DISCLOSURE OF CONFLICTS OF INTEREST
Medical Education Resources insures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies relevant financial relationships with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Reported relevant financial relationships are mitigated by MER to ensure that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing learners with high-quality CE activities that promote improvements or quality in health care and not the business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

*Name of Faculty*	*Reported Financial Relationship*
Dana McCormick, RPh, FAMCP	Dana McCormick, RPh, FAMCP has nothing to disclose.
Jacqueline A. Nicholas, MD, MPH	Research Grants: Biogen, Novartis, PCORI, Genentech, University of Buffalo. Consulting: Consulting: EMD Serono, Genentech, Greenwich Biosciences, Novartis, TG Therapeutics.
Melissa Barnhill, MPH	Melissa Barnhill, MPH has nothing to disclose.

The content managers reported the following financial relationships with ineligible companies whose products or services may be mentioned in this activity:

*Name of Content Manager*	*Reported Financial Relationship*
MER Content Managers	No financial relationships to disclose.
Impact Education, LLC Staff	No financial relationships to disclose.

DISCLAIMER
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, the Multiple Sclerosis Association of America, Impact Education, LLC, and/or Biogen and Novartis. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

METHOD OF PARTICIPATION AND REQUEST FOR CREDIT
There are no fees for participating and receiving CME/CE credit for this activity. During the accreditation period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) and complete the evaluation form. Upon completion of the full CME/CE activity, your certificate will be made available immediately to download and print.

For Pharmacists: Upon successfully completing the activity evaluation form, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

MEDIA
Internet

FEE INFORMATION
There is no fee for this educational activity.